1. Long‐Term Statin Use Is Associated With Reduced Rates of Adverse Events in Patients With Newly Diagnosed Atrial Fibrillation
- Author
-
Ting‐Chun Huang, Li‐Hao Yap, Chao‐Yu Chen, Hui‐Wen Lin, Sheng‐Hsiang Lin, and Yi‐Heng Li
- Subjects
atrial fibrillation ,myocardial infarction ,statin ,stroke ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background The effectiveness of statin use in preventing adverse cardiovascular events in individuals with atrial fibrillation (AF) has remained uncertain. This study aimed to assess whether statin use could lead to better outcomes among individuals with AF. Methods and Results We enrolled 397 787 patients with AF from January 1, 2012 to December 31, 2020. Patients with AF were divided into 2 groups (statin user and statin nonuser), and the risks of composite outcomes (including ischemic stroke, hemorrhagic stroke, and transient ischemic attack), all‐cause death, and major adverse cardiovascular events (which encompassed cardiovascular death, myocardial infarction, stroke, and heart failure hospitalization) were analyzed. We analyzed 288 958 patients with newly diagnosed AF (mean age, 73 years; 44% women; mean CHA2DS2‐VASc score, 3.5). Compared with patients without statin use, statin users had lower risks of composite end points (adjusted hazard ratio [HR], 0.91 [95% CI, 0.87–0.94]; P
- Published
- 2024
- Full Text
- View/download PDF